

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	20/WA/0098	275346	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy	No		17			05/09/2019	12/10/2020	29/04/2020	06/10/2020	29/10/2020	30/10/2020	F - No patients seen	Neither
2	19/LO/0408	257662	PROMISE UK: Percutaneous Deep Vein Arterialization with the Limflow System	No		145			10/09/2020	22/10/2020	03/05/2019	08/03/2021	16/03/2021	17/03/2021	B - Suspended by sponsor	Neither
3	19/SC/0634	252084	Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)	No					23/01/2020	28/10/2020	04/08/2020				B - Suspended by sponsor	Neither
4	20/YH/0133	278290	Nasal High-Flow Oxygen Therapy After Cardiac Surgery (NOTACS) Study: Effect of High-Flow Nasal Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled Trial.	No		252			26/03/2020	30/10/2020	19/06/2020	16/07/2021	09/07/2021		B - Suspended by sponsor	Neither
5	20/SC/0433	282917	Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over	Yes	30/09/2021	264	44	308	30/10/2020	26/11/2020	05/01/2021	08/01/2021	17/08/2021	18/08/2021	B - Suspended by sponsor	Neither
6	20/NW/0183	1003230	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When added to Background Care for the Treatment of Calciphylaxis.	No		11			29/01/2020	10/12/2020	21/05/2020	15/12/2020	21/12/2020	21/01/2021	I - Rare diseases	Neither
7	17/EE/0368	213669	STRESS-L: SStudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	No					07/10/2020	11/12/2020	10/11/2017				E - Staff availability issues	NHS Provider
8	20/LO/1102	281671	RESPONSE - Breaking up prolonged sitting in people with type 2 diabetes: Optimising the response..	No		31			09/06/2020	21/12/2020	19/11/2020	07/01/2021	21/01/2021	08/03/2021	D - Sponsor Delays	Sponsor

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
9	19/NE/0145	254931	FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma	No		22			05/02/2019	30/12/2020	22/07/2019	08/01/2021	21/01/2021	12/02/2021	B - Suspended by sponsor	Neither
10	20/WS/0070	275797	A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction =40% (LVEF= 40%).	No		83			21/04/2020	19/01/2021	04/06/2020	13/04/2021	12/04/2021	23/04/2021	F - No patients seen	Neither
11	20/YH/0339	282343	The impact of a fat rich preload before a carbohydrate-rich meal on glucose homeostasis in patients without diabetes after sleeve gastrectomy: A proof-of-concept, randomised, open-label, crossover study	No					15/07/2020	26/01/2021	26/01/2021	28/01/2021			B - Suspended by sponsor	Neither
12	20/LO/0223	274833	A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	No		7			26/02/2020	28/01/2021	11/06/2020	04/12/2020	04/02/2021	01/03/2021	D - Sponsor Delays	Sponsor
13	20/NI/0131	278283	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT	Yes	26/07/2021	23	220	243	13/08/2020	25/11/2020	21/10/2020	07/12/2020	18/12/2020	05/01/2021	B - Suspended by sponsor	Neither
14	20/EM/0252	282573	A pilot feasibility study of an online Self-Management Intervention through Lifestyle Education for Kidney health (SMILE-K)	Yes	28/07/2021	70	161	231	03/07/2020	09/12/2020	19/11/2020	03/02/2021	17/02/2021	17/02/2021	E - Staff availability issues	NHS Provider

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
15	18/EM/0271	247800	All Inclusive KODEX ? EPD? Study; Patient Specific Optimized Therapy (PSOT) Study	No					05/09/2018	18/02/2021	18/01/2021				B - Suspended by sponsor	Neither
16	21/FT/0038	288581	A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate to severe chronic hand eczema (DELTA 1)	No		181			08/10/2020	04/03/2021	08/06/2021	19/08/2021	01/09/2021		D - Sponsor Delays	Sponsor
17	20/SS/0001	271643	Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischemic, Inflammatory and Takotsubo cardiomyopathy (MEMORY)	No		158			04/03/2021	05/03/2021	04/05/2021	28/07/2021	10/08/2021		D - Sponsor Delays	Sponsor
18	20/NE/0253	288479	COVID-NURSE: evaluation of the effects of a COVID-specific fundamental nursing care protocol compared to care as usual on experience of care for non-invasively ventilated patients in hospital with the SARS-CoV-2 virus: a randomised controlled trial.	Yes	27/04/2021	11	42	53	05/10/2020	05/03/2021	11/11/2020	04/02/2021	16/03/2021			
19	20/LO/0848	272164	ALLTogether1? A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)	No		181			17/09/2020	23/03/2021	25/01/2021	17/09/2021	20/09/2021		D - Sponsor Delays	Sponsor
20	21/EM/0026	286182	Remission of diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction in England and Canada:THE RESET FOR REMISSION TRIAL	No		63			18/03/2021	24/03/2021	17/03/2021	21/04/2021	26/05/2021	14/06/2021	D - Sponsor Delays	Sponsor
21	19/WM/0251	264348	Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia	Yes	12/04/2021	9	178	187	01/08/2019	07/10/2020	07/11/2019	19/11/2020	16/10/2020	29/01/2021	D - Sponsor Delays	Sponsor

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Confirmed and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
22	20/NE/0171	279531	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)	Yes	15/06/2021	35	152	187	01/12/2020	10/12/2020	04/09/2020	18/12/2020	14/01/2021	14/01/2021	F - No patients seen	Neither
23	20/WM/0054	264593	CRAFFT ? Children?s Radius - Acute Fracture Fixation Trial: A multi-centre prospective randomised non-inferiority trial of surgical reduction versus non-surgical casting for displaced distal radius fractures in children.	No					14/10/2020	30/03/2021	16/04/2020				C - Closed by sponsor	Sponsor
24	21/LO/0185	290502	Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients with Symptomatic Heart Failure with Reduced Ejection Fraction and Receiving Spironolactone (REALIZE-K)	No		155			11/02/2021	30/03/2021	29/03/2021	04/08/2021	01/09/2021	08/09/2021	F - No patients seen	Neither
25	20/NI/0100	1003344	A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence	No		11			24/06/2020	09/04/2021	22/10/2020	19/04/2021	20/04/2021	07/05/2021	D - Sponsor Delays	Sponsor
26	20/SS/0089	266798	Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis (MTB) in bronchoalveolar lavage (BAL) for pulmonary TB and endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) samples for mediastinal TB.	Yes	09/09/2021	118	51	169	16/03/2021	24/03/2021	08/10/2020	19/02/2021	20/07/2021	20/07/2021	B - Suspended by sponsor	Neither

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
27	21/SC/0172	289997	Rehabilitation for Cardiac Arrhythmia in COVID-19 and non COVID-19 patients.	No		78			15/04/2021	15/04/2021	03/06/2021	07/06/2021	02/07/2021	02/07/2021	B - Suspended by sponsor	Neither
28	21/YH/0048	291077	An observational post-marketing study for evaluation of ongoing safety and effectiveness of catheter mapping and ablation using commercially approved BWI medical devices for the treatment of patients with cardiac arrhythmias	Yes	21/09/2021	99	68	167	02/04/2021	07/04/2021	01/04/2021	15/07/2021	15/07/2021	10/09/2021	B - Suspended by sponsor	Sponsor
29	20/EM/0081	276533	A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma.	Yes	05/07/2021	54	111	165	09/01/2020	21/01/2021	30/11/2020	15/03/2021	16/03/2021	06/04/2021	B - Suspended by sponsor	Sponsor
30	20/LO/1114	1003435	A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with palbociclib compared with letrozole combined with palbociclib in women with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer	No		15			08/01/2021	21/04/2021	08/12/2020	05/05/2021	06/05/2021	12/05/2021	F - No patients seen	Neither
31	21/SC/0076	291410	An single centre, prospective, pharmacokinetic study of intravenous voriconazole used for treatment of invasive aspergillosis in adult patients with severe influenza / COVID-19 supported with extra-corporeal membrane oxygenation (ECMO)	No		110			23/02/2021	22/04/2021	06/05/2021	18/03/2021	10/08/2021	10/08/2021	B - Suspended by sponsor	Sponsor

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
32	20/LO/0938	1003322	Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.	No		11			01/01/2019	29/04/2021	13/11/2020	08/05/2021	10/05/2021	01/10/2021	D - Sponsor Delays	Sponsor
33	20/LO/0639	281304	A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.	Yes	13/04/2021	33	112	145	05/11/2019	19/11/2020	01/06/2020	21/12/2020	22/12/2020	22/12/2020	F - No patients seen	Neither
34	17/LO/0054	199080	Prospective randomised trial of digital breast tomosynthesis (DBT) plus standard 2D digital mammography (2DDM) or synthetic 2D mammography (S 2D) compared to standard 2D digital mammography in breast cancer screening.	No		150			15/10/2020	11/05/2021	13/02/2017	08/10/2021	08/10/2021		D - Sponsor Delays	Sponsor
35	21/LO/0243	291403	Multicentre prospective single-blind wait-list randomised controlled trial, with nested pilot, of the clinical value and economic evaluation of an online physical and emotional wellbeing resource for the improvement of health-related quality of life in people with chronic kidney disease: The Kidney Beam Trial	Yes	07/10/2021	77	65	142	08/04/2021	18/05/2021	13/04/2021	18/08/2021	03/08/2021	03/09/2021	D - Sponsor Delays	Sponsor
36	21/SC/0121	294861	HElping Alleviate the Longer-term consequences of COVID-19(HEAL-COVID): a national platform trial	No		4			07/04/2021	17/05/2021	08/04/2021	26/04/2021	21/05/2021	25/05/2021	F - No patients seen	Neither
37	20/WM/0275	280452	A randomised controlled trial assessing the effectiveness and cost effectiveness of thrice weekly, extended, in-centre nocturnal haemodialysis versus standard care using a mixed methods approach	No		28			02/06/2020	20/05/2021	11/12/2020	14/06/2021	17/06/2021	24/06/2021	J - Other	Neither

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
38	20/EM/0097	277324	Gluteal Turnover Flap For Closure of the Perineal Wound after Abdominoperineal Resection for Rectal Cancer	No		12			12/06/2020	26/05/2021	19/05/2020	27/03/2021	07/06/2021	07/06/2021	F - No patients seen	Neither
39	20/LO/1110	284958	Pregnancy ANtiHypertensive Drugs: which Agent is best?	Yes	15/07/2021	111	14	125	12/03/2021	12/03/2021	17/12/2020	30/06/2021	01/07/2021	14/07/2021	B - Suspended by sponsor	Neither
40	20/LO/0944	1003371	SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer	Yes	14/07/2021	24	97	121	24/02/2021	15/03/2021	27/08/2020	31/03/2021	08/04/2021	18/05/2021	D - Sponsor Delays	Sponsor
41	20/SC/0403	288652	PROphylaxis for paTIEnts at risk of COVID-19 infecTion	Yes	25/08/2021	6	106	112	21/03/2021	05/05/2021	22/12/2020	10/05/2021	11/05/2021	27/05/2021	J - Other	Neither
42	21/NI/0001	1003373	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC: Master (KEYNOTE-U03)	No		10			18/02/2021	11/06/2021	23/03/2021	22/06/2021	21/06/2021	02/08/2021	B - Suspended by sponsor	Sponsor
43	20/LO/1090	288214	A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Yes	24/05/2021	1	109	110	18/09/2021	03/02/2021	23/10/2020	28/01/2021	04/02/2021	08/02/2021	F - No patients seen	Neither
44	21/LO/0190	293785	Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis	Yes	27/09/2021	49	59	108	20/01/2021	11/06/2021	23/04/2021	29/06/2021	30/07/2021	23/09/2021	F - No patients seen	Neither
45	20/NW/0234	276873	Suture fixation versus tension band wiring for simple olecranon fracture fixation: a multi-centre randomised controlled trial (Simple Olecranon Fracture Fixation Trial ? SOFFT)	No		7			15/06/2020	17/06/2021	16/06/2020	25/06/2021	24/06/2021		D - Sponsor Delays	Sponsor
46	20/SC/0423	288506	Evaluating the clinical and cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care.	Yes	26/07/2021	56	45	101	07/04/2021	16/04/2021	19/02/2021	27/05/2021	11/06/2021	26/07/2021	D - Sponsor Delays	Sponsor

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
47	17/LO/1372	203851	A single centre, open label Randomised Controlled Trial of the RAPID?* PRP (Platelet Rich Plasma) Haematogel Wound Care Treatment in addition to Usual and Customary Care, (UCC); compared to Usual and Customary Care (UCC) alone, in the management of adult patients with chronic Diabetic Foot Ulcers. RAPID?* [Restorative Autologous Platelet biotherapies for treatment of Injuries & Delayed wound healing] Biodynamic Platelet Rich Plasma [PRP] Haematogel	No		17			10/06/2021	21/06/2021	30/11/2018	21/05/2021	08/07/2021		D - Sponsor Delays	Sponsor
48	21/LO/0394	1003768	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF OTO-313 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL SUBJECTIVE TINNITUS	No					12/04/2021	22/06/2021	21/06/2021				A - Permissions delayed/denied D - Sponsor Delays	Sponsor
49	18/LO/2070	246179	A feasibility trial of serial prophylactic exchange blood transfusion (SPEBT) in pregnant women with sickle cell disease (SCD) aiming to improve maternal and infant outcomes	No					12/03/2021	22/06/2021	28/03/2019				D - Sponsor Delays	Sponsor
50	20/WM/0220	285844	A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope? IMCY-0098 and its effect on the preservation of beta-cell function in young adult and adolescent patients with a recent onset Type 1 diabetes	No		14			28/05/2021	01/07/2021	11/09/2020	12/07/2021	15/07/2021		D - Sponsor Delays	Sponsor
51	20/WM/0306	290913	A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL	No		15			12/06/2021	05/07/2021	07/01/2021	08/07/2021	20/07/2021	22/07/2021	F - No patients seen	Neither

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
52	21/LO/0080	293186	A randomised open label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio?) after rationalisation of nebulised mucoactive therapies (the CF STORM trial)	No					22/04/2021	07/07/2021	10/03/2021				D - Sponsor Delays	Sponsor
53	20/SC/0365	1003436	A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC)	Yes	18/06/2021	21	63	84	21/08/2020	26/03/2021	13/11/2020	16/04/2021	16/04/2021	23/04/2021	F - No patients seen	Neither
54	20/LO/1059	287861	An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301	Yes	27/05/2021	29	50	79	14/07/2020	09/03/2021	23/11/2020	07/04/2021	07/04/2021	13/04/2021	F - No patients seen	Neither
55	20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).	Yes	23/06/2021	9	69	78	30/07/2020	06/04/2021	25/09/2020	10/02/2021	15/04/2021	12/05/2021	D - Sponsor Delays	Sponsor
56	19/YH/0054	258802	A pragmatic, multicentre, randomised controlled trial to assess the clinical and cost effectiveness of negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention (SWHSI 2)	No		69			16/07/2021	20/07/2021	05/04/2019	23/09/2021	27/09/2021		D - Sponsor Delays	Sponsor
57	20/NW/0381	1003380	A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer	No					11/12/2020	21/07/2021	16/11/2020				D - Sponsor Delays	Sponsor

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
58	19/NE/0215	234453	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	Yes	16/12/2020	1	68	69	01/05/2018	08/10/2020	07/11/2019	28/10/2020	09/10/2020	29/10/2020		
59	20/EM/0015	247350	Beyond Allergic Th2 Severe Asthma	No		7			15/02/2021	27/07/2021	25/03/2020	22/07/2021	03/08/2021	12/08/2021		
60	21/EM/0015	286239	Pre-operative weight management to improve outcomes of cardiac surgery in adults with obesity (SLIM-CARD): a multicentre feasibility RCT	No		14			13/03/2018	27/07/2021	11/02/2021	03/08/2021	10/08/2021			
61	21/WS/0044	1003689	A Randomised, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer.	No		10			08/01/2021	09/08/2021	15/06/2021	16/08/2021	19/08/2021		D - Sponsor Delays	Sponsor
62	19/LO/1633	271207	ADAPT - ADvanced Hybrid Closed Loop study in Adult Population with Type 1 Diabetes	Yes	05/03/2021	42	10	52	08/12/2020	12/01/2021	31/12/2019	10/02/2021	23/02/2021	26/02/2021		
63	20/WA/0019	271876	Randomised controlled trial of contrast enhanced colonoscopy in the reduction of right sided bowel cancer. (The CONSCOP 2 study)	No					21/01/2021	12/08/2021	26/02/2021					
64	21/LO/0211	1003620	An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Cardiovascular Outcomes in Patients on Chronic Dialysis with Recurrent Hyperkalaemia (DIALIZE-Outcomes)	Yes	31/08/2021	1	47	48	20/01/2021	14/07/2021	10/05/2021	12/07/2021	15/07/2021	12/08/2021		

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
65	19/SW/0043	235625	CHIEF-PD (Cholinesterase Inhibitor to prevent Falls in Parkinson's Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease	No		65			06/08/2021	18/08/2021	26/07/2019		22/10/2021			
66	20/SC/0189	278270	A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)	Yes	08/12/2020	16	26	42	27/10/2020	27/10/2020	10/07/2020	29/10/2020	12/11/2020	20/11/2020		
67	20/ES/0122	1003500	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort? UD in Ocular Hypertensive or Glaucomatous Patients	No		3			17/11/2020	20/08/2021	01/02/2021	20/08/2021	23/08/2021			
68	21/WA/0050	280904	Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults ? A Randomised Double-Blind Placebo-Controlled Trial	No					04/08/2021	26/08/2021	05/05/2021					
69	20/HRA/5234	290965	A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19	Yes	16/02/2021	13	21	34	13/01/2021	13/01/2021	09/11/2020	26/01/2021	26/01/2021	26/01/2021		
70	20/EE/0289	281882	DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controlled clinical trial	No		22			03/06/2021	30/08/2021	22/01/2021	13/09/2021	21/09/2021	23/09/2021		
71	21/EM/0084	288873	The development and feasibility testing of a Pulmonary Rehabilitation Shared Decision Making intervention for patients with Chronic Obstructive Pulmonary Disease	Yes	14/06/2021	28	0	28	01/02/2021	17/05/2021	14/05/2021	14/06/2021	14/06/2021	14/06/2021		

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
72	21/LO/0157	1003549	Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies	No		24			11/05/2021	03/09/2021	13/04/2021	23/09/2021	27/09/2021			
73	21/SC/0171	299180	A randomised phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-COV-2	Yes	02/06/2021	16	7	23	15/04/2021	10/05/2021	17/05/2021	19/05/2021	26/05/2021	01/06/2021		
74	19/EM/0070	237774	A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN)	No		34			12/02/2019	10/09/2021	24/05/2019	24/09/2021	14/10/2021			
75	20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Heart Failure or Cardiovascular Death in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure	Yes	26/04/2021	8	11	19	17/06/2020	07/04/2021	23/07/2020	14/04/2021	15/04/2021	21/04/2021		
76	21/FT/0070	297587	A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess the Immunological Response and Safety Profile of a Single Dose BPZE1 With and Without Co-Administration of Tetanus, Diphtheria, and Acellular Pertussis (Boostrix?)	No		34			10/03/2021	15/09/2021	18/08/2021	19/10/2021	19/10/2021			

Row ID	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
77	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Yes	25/11/2020	9	4	13	08/10/2020	12/11/2020	10/11/2020	20/11/2020	21/11/2020	25/11/2020		
78	21/HRA/3072	302634	A Phase III, Multicentre, Randomised Trial Comparing SARS-CoV-2 Re-Boost Vaccine Strategies in Immunocompromised Patients	No		5			12/07/2021	23/09/2021	22/07/2021	28/09/2021	28/09/2021	01/10/2021		